Hyperparathyroidism and Bone Health

Osteoporosis and Metabolic Bone Disease (S Honig, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Osteoporosis and Metabolic Bone Disease


Bone pain, proximal muscle weakness, skeletal deformities, and pathological fractures are features of osteitis fibrosa cystica which occur in severe primary hyperparathyroidism (PHPT). In this condition, bone mineral density is usually extremely low, but may be reversible after parathyroidectomy. On X-ray, bone abnormalities are described as having a salt-and-pepper appearance in the skull, with bone erosions and resorption of the phalanges, brown tumors and cysts, as well as diffuse demineralization, along with pathological fractures, particularly in the long bones of the extremities. A marked elevation of the serum calcium and PTH concentrations is seen, and renal involvement is manifested by nephrolithiasis and nephrocalcinosis. In asymptomatic PHPT, the absence of clinically significant bone involvement has led to much more data on bone mineral density becoming available by dual X-ray absorptiometry (DXA) and also on new technologies such as trabecular bone score (TBS), which is a gray-level textural analysis of DXA images that provides an indirect index of trabecular microarchitecture. In addition, high-resolution peripheral computed tomography (HRpQCT), which has a low radiation exposure, provides further understanding of the microstructural skeletal features at both trabecular and cortical sites.


Hyperparathyroidism Bone mineral density Bone microarchitecture Vitamin D Calcium PTH Nephrocalcinosis 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Bandeira F, Griz L, Caldas G, Bandeira C, Freese E. From mild to severe primary hyperparathyroidism: the Brazilian experience. Arq Bras Endocrinol Metabol. 2006;50(4):657–63.PubMedCrossRefGoogle Scholar
  2. 2.
    Kulak CA, Bandeira C, Voss D, et al. Marked improvement in bone mass after parathyroidectomy in osteitis fibrosa cystica. J Clin Endocrinol Metab. 1998;83(3):732–5.PubMedGoogle Scholar
  3. 3.
    Silverberg SJ, Clarke B, Peacock M, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J Clin Endocrinol Metab. 2014. doi:10.1210/jc.2014-1415.Google Scholar
  4. 4.
    Zhao L, Liu JM, He XY, et al. The changing clinical patterns of primary hyperparathyroidism in Chinese patients: data from 2000 to 2010 in a single clinical center. J Clin Endocrinol Metab. 2013;98(2):721–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Oliveira UE, Ohe MN, Santos RO, et al. Analysis of the diagnostic presentation profile, parathyroidectomy indication and bone mineral density follow-up of Brazilian patients with primary hyperparathyroidism. Braz J Med Biol Res. 2007;40(4):519–26.PubMedCrossRefGoogle Scholar
  6. 6.
    Eufrazino C, Veras A, Bandeira F. Epidemiology of primary hyperparathyroidism and its non-classical manifestations in the city of Recife, Brazil. Clin Med Insights Endocrinol Diabetes. 2013;6:69–74.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Franca TC, Griz L, Pinho J, et al. Bisphosphonates can reduce bone hunger after parathyroidectomy in patients with primary hyperparathyroidism and osteitis fibrosa cystica. Rev Bras Reumatol. 2011;51(2):131–7.PubMedCrossRefGoogle Scholar
  8. 8.•
    Bandeira F, Griz L, Chaves N, et al. Diagnosis and management of primary hyperparathyroidism—a scientific statement from the Department of Bone Metabolism, the Brazilian Society for Endocrinology and Metabolism. Arq Bras Endocrinol Metab. 2013;57(6):406–24. A broad review on the various forms of clinical presentation of PHPT, including management of severe, asymptomatic, and normocalcemic disease.Google Scholar
  9. 9.
    Bandeira FA, Oliveira RI, Griz LH, Caldas G, Bandeira C. Differences in accuracy of 99mTc-sestamibi scanning between severe and mild forms of primary hyperparathyroidism. J Nucl Med Technol. 2008;36(1):30–5.PubMedCrossRefGoogle Scholar
  10. 10.••
    Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the fourth international workshop. J Clin Endocrinol Metab. 2014. doi:10.1210/jc.2014-1413. An excellent summary of the newest recommendations for the diagnosis and management of asymptomatic PHPT.
  11. 11.
    Udelsman R, Akerström G, Biagini C, et al. The surgical management of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J Clin Endocrinol Metab. 2014. doi:10.1210/jc.2014-2000.Google Scholar
  12. 12.
    Silverberg SJ, Gartenberg F, Jacobs TP, et al. Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J Clin Endocrinol Metab. 1995;80(3):729–34.PubMedGoogle Scholar
  13. 13.
    Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab. 2008;93(9):3462–70.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Brasier AR, Nussbaum SR. Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery. Am J Med. 1988;84(4):654–60.PubMedCrossRefGoogle Scholar
  15. 15.
    Witteveen JE, van Thiel S, Romijn JA, Hamdy NA. Hungry bone syndrome: still a challenge in the post-operative management of primary hyperparathyroidism: a systematic review of the literature. Eur J Endocrinol. 2013;168(3):R45–53.PubMedCrossRefGoogle Scholar
  16. 16.
    Bandeira F, Amaral L, Aragão P. Primary hyperparathyroidism. In: Bandeira F, Gharib H, Golbert A, Griz L, Faria M, editors. Endocrinology and diabetes: a problem-oriented approach. New York: Springer; 2013. p. 279–91.Google Scholar
  17. 17.
    Graal MB, Wolffenbuttel BH. Consequences of long-term hyperparathyroidism. Neth J Med. 1998;53(1):37–42.PubMedCrossRefGoogle Scholar
  18. 18.
    Boyle IT, Fogelman I, Boyce B, et al. 1alpha-hydroxyvitamin D3 in primary hyperparathyroidism. Clin Endocrinol (Oxford). 1977;7 Suppl:215s–22.CrossRefGoogle Scholar
  19. 19.
    Silverberg SJ, Shane E, Jacobs TP, Siris E, Bilezikian JP. A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N Engl J Med. 1999;341(17):1249–55.PubMedCrossRefGoogle Scholar
  20. 20.
    Bandeira F, Cusano N, Silva B, Cassibba S, Almeida C, Machado V, et al. Bone disease in primary hyperparathyroidism. Arch Bras Endocrinol Metab. 2014;58(5):553–61.CrossRefGoogle Scholar
  21. 21.
    Parisien M, Silverberg SJ, Shane E, et al. The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. J Clin Endocrinol Metab. 1990;70(4):930–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Dempster DW, Muller R, Zhou H, et al. Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone. 2007;41(1):19–24.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Khosla S, Melton III LJ, Wermers RA, Crowson CS, O’Fallon WM, Riggs BL. Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res. 1999;14(10):1700–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Vestergaard P, Mollerup CL, Frokjaer VG, Christiansen P, Blichert-Toft M, Mosekilde L. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ. 2000;321(7261):598–602.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Vestergaard P, Mosekilde L. Fractures in patients with primary hyperparathyroidism: nationwide follow-up study of 1201 patients. World J Surg. 2003;27(3):343–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Vignali E, Viccica G, Diacinti D, et al. Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J Clin Endocrinol Metab. 2009;94(7):2306–12.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Yu N, Donnan PT, Flynn RW, et al. Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin Endocrinol (Oxford). 2010;73(1):30–4.Google Scholar
  28. 28.
    Hansen S, Beck Jensen JE, Rasmussen L, Hauge EM, Brixen K. Effects on bone geometry, density, and microarchitecture in the distal radius but not the tibia in women with primary hyperparathyroidism: a case-control study using HR-pQCT. J Bone Miner Res. 2010;25(9):1941–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Stein EM, Silva BC, Boutroy S, et al. Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. J Bone Miner Res. 2013;28(5):1029–40.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Vu TD, Wang XF, Wang Q, et al. New insights into the effects of primary hyperparathyroidism on the cortical and trabecular compartments of bone. Bone. 2013;55(1):57–63.PubMedCentralPubMedCrossRefGoogle Scholar
  31. 31.•
    Silva BC, Leslie WD, Resch H, et al. Trabecular bone score: a non-invasive analytical method based upon the DXA image. J Bone Miner Res. 2014. The authors nicely review interesting data on TBS in asymptomatic PHPT.Google Scholar
  32. 32.
    Hans D, Barthe N, Boutroy S, Pothuaud L, Winzenrieth R, Krieg MA. Correlations between trabecular bone score, measured using anteroposterior dual-energy X-ray absorptiometry acquisition, and 3-dimensional parameters of bone microarchitecture: an experimental study on human cadaver vertebrae. J Clin Densitom. 2011;14(3):302–12.PubMedCrossRefGoogle Scholar
  33. 33.
    Roux JP, Wegrzyn J, Boutroy S, Bouxsein ML, Hans D, Chapurlat R. The predictive value of trabecular bone score (TBS) on whole lumbar vertebrae mechanics: an ex vivo study. Osteoporos Int. 2013;24(9):2455–60.PubMedCrossRefGoogle Scholar
  34. 34.
    Hans D, Goertzen AL, Krieg MA, Leslie WD. Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res. 2011;26(11):2762–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Boutroy S, Hans D, Sornay-Rendu E, Vilayphiou N, Winzenrieth R, Chapurlat R. Trabecular bone score improves fracture risk prediction in non-osteoporotic women: the OFELY study. Osteoporos Int. 2013;24(1):77–85.PubMedCrossRefGoogle Scholar
  36. 36.
    Briot K, Paternotte S, Kolta S, et al. Added value of trabecular bone score to bone mineral density for prediction of osteoporotic fractures in postmenopausal women: The OPUS study. Bone. 2013.Google Scholar
  37. 37.
    Iki M, Tamaki J, Kadowaki E, et al. Trabecular Bone Score (TBS) predicts vertebral fractures in Japanese women over 10 years independently of bone density and prevalent vertebral deformity: the Japanese population-based osteoporosis (JPOS) cohort study. J Bone Miner Res. 2013.Google Scholar
  38. 38.
    Silva BC, Boutroy S, Zhang C, et al. Trabecular bone score (TBS)—a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism. J Clin Endocrinol Metab. 2013;98(5):1963–70.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Romagnoli E, Cipriani C, Nofroni I, et al. “Trabecular bone score” (TBS): an indirect measure of bone micro-architecture in postmenopausal patients with primary hyperparathyroidism. Bone. 2013;53(1):154–9.PubMedCrossRefGoogle Scholar
  40. 40.
    Eller-Vainicher C, Filopanti M, Palmieri S, et al. Bone quality, as measured by trabecular bone score, in patients with primary hyperparathyroidism. Eur J Endocrinol. 2013;169(2):155–62.PubMedCrossRefGoogle Scholar
  41. 41.
    Hansen S, Hauge EM, Rasmussen L, Jensen JE, Brixen K. Parathyroidectomy improves bone geometry and microarchitecture in female patients with primary hyperparathyroidism: a one-year prospective controlled study using high-resolution peripheral quantitative computed tomography. J Bone Miner Res. 2012;27(5):1150–8.PubMedCrossRefGoogle Scholar
  42. 42.•
    Lundstam K, Heck A, Mollerup C, Godang K, Baranowski M, Pernow Y, et al. Effects of parathyroidectomy versus observation on the development of vertebral fractures in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2015. doi:10.1210/jc.2014-3441. A randomized-controlled study on the effects of parathyroidectomy in asymptomatic PHPT.
  43. 43.
    Pimentel L, Portela S, Loureiro A, Bandeira F. Normocalcemic primary hyperparathyroidism: long-term follow-up associated with multiple adenomas. Arq Bras Endocrinol Metabol. 2014;58(5):583–6.PubMedCrossRefGoogle Scholar
  44. 44.••
    Cusano NE, Silverberg SJ, Bilezikian JP. Normocalcemic primary hyperparathyroidism. J Clin Densitom. 2013;16(1):33–9. A good literature review on the various aspects of normocalcemic PHPT as well as the research gaps which need to be fulfilled.Google Scholar
  45. 45.
    Hagström E, Lundgren E, Rastad J, Hellman P. Metabolic abnormalities in patients with normocalcemic hyperparathyroidism detected at a population-based screening. Eur J Endocrinol. 2006;155(1):33–9.PubMedCrossRefGoogle Scholar
  46. 46.
    Tordjman KM, Yaron M, Izkhakov E, Osher E, Shenkerman G, Marcus-Perlman Y, et al. Cardiovascular risk factors and arterial rigidity are similar in asymptomatic normocalcemic and hypercalcemic primary hyperparathyroidism. Eur J Endocrinol. 2010;162(5):925–33.PubMedCrossRefGoogle Scholar
  47. 47.
    Tordjman KM, Greenman Y, Osher E, et al. Characterization of normocalcemic primary hyperparathyroidism. Am J Med. 2004;117:861–3.PubMedCrossRefGoogle Scholar
  48. 48.
    Koumakis E, Souberbielle JC, Sarfati E, Meunier M, Maury E, Gallimard E, et al. Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism. J Clin Endocrinol Metab. 2013;98(8):3213–20.PubMedCrossRefGoogle Scholar
  49. 49.
    Lowe H, McMahon D, Rubin M, Bilezikian J, Silverberg S. Normocalcemic primary hyperparathyroidism: further characterization of a new clinical phenotype. J Clin Endocrinol Metab. 2007;92(8):3001–5.PubMedCrossRefGoogle Scholar
  50. 50.
    Garcia-Martin A, Reyes-Garcia R, Munoz-Torres M. Normocalcemic primary hyperparathyroidism: one-year follow-up in one hundred postmenopausal women. Endocrine. 2012.Google Scholar
  51. 51.
    Amaral LM, Queiroz DC, Marques TF, Mendes M, Bandeira F. Normocalcemic versus hypercalcemic primary hyperparathyroidism: more stone than bone? J Osteoporos. 2012.Google Scholar
  52. 52.
    Charopoulos I, Tournis S, Trovas G, et al. Effect of primary hyperparathyroidism on volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in postmenopausal women. J Clin Endocrinol Metab. 2006;91:1748–53.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Division of Endocrinology, Diabetes and Bone Diseases, Agamenon Magalhães Hospital, Brazilian Ministry of HealthUniversity of Pernambuco Medical SchoolRecifeBrazil
  2. 2.Division of Endocrinology and MetabolismPapa Giovanni XXIII HospitalBergamoItaly

Personalised recommendations